# Definium Phase 3 Emerge Trial of LSD-Based DT120 Meets Primary Endpoint in Major Depression

> clinical trial · REPORTED · 2026-06-22

Definium Therapeutics (formerly MindMed) announced positive topline results from its Phase 3 Emerge study: a single 100-microgram dose of DT120 (lysergide ODT) produced a statistically significant placebo-adjusted MADRS score improvement of 8.1 points at week six versus placebo (p less than 0.0001). Shares surged approximately 53% on the news, marking the first positive pivotal Phase 3 result for a lysergide-based therapy.

- Company: Definium Therapeutics
- Sector: mental health
- Primary source: https://ir.definiumtx.com/news-events/press-releases/detail/231/definium-therapeutics-to-discuss-topline-results-from-phase-3-emerge-study-in-major-depressive-disorder-on-june-22-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.